Related Experiment Videos
Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients
G Testa1, J S Crippin, G J Netto
1Baylor University Medical Center, Transplantation Services, Dallas, TX 75246, USA.
Insights
Hepatitis C recurrence after liver transplant is common, often within two years. Early recurrence significantly impacts patient and graft survival, highlighting the need for further research into host factors and the virus-rejection-immunosuppression relationship.
Area of Science:
- Hepatology
- Transplantation Immunology
- Virology
Background:
- Hepatitis C recurrence post-orthotopic liver transplantation (OLT) impacts long-term outcomes.
- The precise timing and progression of allograft damage are not fully understood.
Purpose of the Study:
- To analyze the incidence, timing, and risk factors of hepatitis C recurrence after OLT.
- To evaluate the impact of recurrence on disease progression, patient survival, and graft survival.
- To investigate the relationship between recurrence, rejection, and immunosuppression.
Main Methods:
- Retrospective analysis of 300 patients undergoing OLT for hepatitis C.
- Evaluation of histological recurrence, risk factors, immunosuppressive regimens, and rejection episodes.
- Analysis of disease progression, retransplantation data, and survival rates.
Main Results:
- Histological recurrence occurred in 40.3% of patients, with 27.2% progressing to fibrosis or cirrhosis.
- Eighty-seven percent of recurrences happened within 24 months post-OLT.
- Early recurrence (within 6 months) significantly increased cirrhosis risk (RR, 2.3) and was associated with decreased 1- and 5-year survival rates.
- Recurrent hepatitis C was linked to higher rates of acute cellular rejection, multiple rejection episodes, and increased corticosteroid use.
Conclusions:
- Hepatitis C recurrence post-OLT is frequent, typically within two years, and early recurrence adversely affects survival.
- Further investigation into host factors influencing recurrence is warranted.
- The interplay between hepatitis C virus, allograft rejection, and immunosuppression requires deeper study.
Abstract:
The time progression of allograft damage in patients with recurrent hepatitis C after orthotopic liver transplantation (OLT) is not precisely determined. The aim of this analysis is to study the progression of disease recurrence and its impact on patient and graft survival. Data for 300 patients who underwent OLT for hepatitis C were analyzed regarding the incidence of histological recurrence, risk factors, immunosuppressive regimen, rejection episodes, and survival. For patients with histological recurrence, the timing and risks for disease progression were analyzed. Data for 30 patients who underwent retransplantation were studied. Histological recurrence occurred in 40.3% of patients, 27.2% of whom progressed to bridging fibrosis or cirrhosis. Eighty-seven percent of the patients experienced recurrence of disease within 24 months of OLT. Patients with histological recurrence within 6 months of OLT had an increased risk for progression to cirrhosis compared with patients with recurrence later than 6 months (risk ratio, 2.3). Recurrence within 1 year was associated with decreased patient and graft survival rates at 1 and 5 years (65.1% and 56.4% versus 80.6% and 78.4%; P =.004 and P =.0008, respectively). Patients with histological recurrence had a greater incidence of acute cellular rejection, as well as multiple episodes of rejection, steroid-resistant rejections, and greater cumulative doses of corticosteroids. Histological recurrence after OLT for hepatitis C is common and usually occurs within 2 years of OLT. Early recurrence negatively affects patient and graft survival. Host factors impacting on recurrence need further study. A relation between the hepatitis C virus, allograft rejection, and immunosuppression exists and needs investigation.